Literature DB >> 28681549

Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.

Angela Fischer1, Sara Bastian1, Sergio Cogliatti2, Ulrich Mey1, Jenny Saub3, Urs Schanz3, Barbara Padberg4, Karin Hohloch1,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28681549     DOI： 10.1002/hon.2464

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  4 in total

1.  ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.

Authors:  Tiziana Vaisitti; Francesca Arruga; Nicoletta Vitale; Thanh-Trang Lee; Mira Ko; Amy Chadburn; Esteban Braggio; Arianna Di Napoli; Andrea Iannello; John N Allan; Langdon L Miller; Brian J Lannutti; Richard R Furman; Katti A Jessen; Silvia Deaglio
Journal:  Blood       Date:  2021-06-17       Impact factor: 22.113

Review 2.  Novel Approaches for the Treatment of Patients with Richter's Syndrome.

Authors:  Andrea Iannello; Silvia Deaglio; Tiziana Vaisitti
Journal:  Curr Treat Options Oncol       Date:  2022-03-16

Review 3.  Richter Syndrome: From Molecular Pathogenesis to Druggable Targets.

Authors:  Samir Mouhssine; Gianluca Gaidano
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

4.  Successful treatment of "accelerated" chronic lymphocytic leukemia with single agent ibrutinib: A report of two cases.

Authors:  John Xie; Albert Jang; Andrew Vegel; Yasmin Hajja; Yara Mouawad; Ali Baghian; Bachir Berbari; Janet L Schmid; Francisco Socola; Hana Safah; Nakhle S Saba
Journal:  Leuk Res Rep       Date:  2021-05-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.